Form 8-K - Current report:
SEC Accession No. 0000950170-23-011689
Filing Date
2023-04-04
Accepted
2023-04-04 07:01:00
Documents
12
Period of Report
2023-04-02
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K gls-20230402.htm   iXBRL 8-K 56823
  Complete submission text file 0000950170-23-011689.txt   178479

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gls-20230402_lab.xml EX-101.LAB 13904
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gls-20230402_pre.xml EX-101.PRE 10225
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gls-20230402.xsd EX-101.SCH 2460
6 EXTRACTED XBRL INSTANCE DOCUMENT gls-20230402_htm.xml XML 4881
Mailing Address 501 BOYLSTON STREET, SUITE 6102 BOSTON MA 02116
Business Address 501 BOYLSTON STREET, SUITE 6102 BOSTON MA 02116 857-327-7737
GELESIS HOLDINGS, INC. (Filer) CIK: 0001805087 (see all company filings)

EIN.: 844730610 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39362 | Film No.: 23795067
SIC: 2834 Pharmaceutical Preparations